Imunon Inc (IMNN) Stock Price, Quote & News

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 896 9100

Website: imunon.com

Address:

997 Lenox Drive, Suite 100, Lawrenceville, United States

jjegglie Sep. 16 at 8:40 PM

$IMNN I provide celsion life lessons at zero cost, yet so many choose to think they know more about this stock promotion scam corporation than me and learn their own lessons at great cost.

0 · Reply

Golferhack12 Sep. 16 at 7:36 PM

$IMNN hitting an all-time low today just a complete disaster never any news never anything the only reason the stock is above water is because of the reverse split it's actually trading at about 9 cents

0 · Reply

3ARated Sep. 16 at 2:37 PM

$IMNN When do they turn out the lights?

1 · Reply

WavyTraders Sep. 12 at 8:45 PM

Looks like ALL volume and momentum are shifting in to CMCT! Shorts overextended and now bulls can have them trapped at the bottom. CMCT Could pull a huge multi day run - only 700k float! Don't miss CMCT..,it's breaking out! $ASST $GME $HSDT $IMNN

1 · Reply

HiPpYcHoP Sep. 11 at 9:51 PM

$IMNN WhaT’s GoiN oN? We MoViN AH!

0 · Reply

ddgcabd Sep. 11 at 1:26 PM

$IMNN $LLY $AZN $JNJ As soon as you come to grips with the fact that celsion doesn't give a single shit about cancer, everything they do starts to make perfect sense.

0 · Reply

ConcernedCitizen23 Sep. 11 at 11:46 AM

$IMNN I’ve posted about this before but check on your own. They are doing a “look again” phase 2 at Sloan Kettering, Johns Hopkins and MD Anderson for tissue proof of concept where they will rebiopsy the women after treatment. The CEO alluded to that research coming out within a year. Also the women who go to those places have sons and husbands in Hedge Funds. Imagine hearing your mother survived cancer due to $IMNN ! The money spigot will open big! $LLY $AZN $JNJ

0 · Reply

I_AM_GROOT Sep. 11 at 12:26 AM

$IMNN doubt it was from her personal cash. Bonuses can come via stock .

1 · Reply

Charleygolden Sep. 10 at 6:59 PM

$IMNN AKA $.37.

0 · Reply

Phil212 Sep. 10 at 12:25 PM

$IMNN So it looks like a 4 Form was filed last night. Stacy Lindborg has purchased a huge 1667 shares in the company, now holding 3584 shares, with an additional 234 shares in her 401k. Come on Stacy, you can do better than that 😂😂😂

2 · Reply

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Aug 5, 2025, 4:00 PM EDT - 6 weeks ago

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Aug 5, 2025, 1:26 PM EDT - 6 weeks ago

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 6 weeks ago

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:05 AM EDT - 6 weeks ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Jul 29, 2025, 8:30 AM EDT - 7 weeks ago

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

Jul 28, 2025, 8:05 AM EDT - 7 weeks ago

IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 23, 2025, 8:00 AM EDT - 7 weeks ago

IMUNON Announces Reverse Stock Split

Jul 15, 2025, 8:05 AM EDT - 2 months ago

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Jun 18, 2025, 8:05 AM EDT - 3 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 17, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 3, 2025, 8:05 AM EDT - 3 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 2, 2025, 8:05 AM EDT - 3 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

May 27, 2025, 8:05 AM EDT - 4 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 23, 2025, 6:59 PM EDT - 4 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 22, 2025, 5:20 PM EDT - 4 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 15, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 12, 2025, 12:56 PM EDT - 4 months ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 8:00 AM EDT - 4 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 6, 2025, 8:05 AM EDT - 4 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 5, 2025, 8:00 AM EDT - 4 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

Apr 21, 2025, 8:05 AM EDT - 5 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 6 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Feb 27, 2025, 2:32 PM EST - 7 months ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 8:05 AM EST - 7 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 26, 2025, 8:05 AM EST - 7 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 20, 2025, 8:30 AM EST - 7 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 19, 2025, 8:05 AM EST - 7 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 10, 2025, 8:05 AM EST - 7 months ago

IMUNON Appoints Douglas V. Faller, M.D.

Dec 19, 2024, 8:05 AM EST - 9 months ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 10, 2024, 8:05 AM EST - 10 months ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Nov 25, 2024, 8:05 AM EST - 10 months ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Nov 7, 2024, 5:11 PM EST - 11 months ago

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:00 AM EST - 11 months ago

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Nov 7, 2024, 8:05 AM EST - 11 months ago

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 31, 2024, 8:30 AM EDT - 11 months ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

Oct 30, 2024, 9:05 AM EDT - 11 months ago

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Oct 7, 2024, 8:05 AM EDT - 1 year ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 9, 2024, 4:06 PM EDT - 1 year ago

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

Aug 28, 2024, 8:30 AM EDT - 1 year ago

IMUNON to Host R&D Day on September 18th

Aug 14, 2024, 2:55 PM EDT - 1 year ago

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 7, 2024, 5:04 PM EDT - 1 year ago

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

Jul 30, 2024, 1:07 PM EDT - 1 year ago

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Jul 30, 2024, 9:42 AM EDT - 1 year ago

Imunon's stock rockets after ovarian cancer treatment's positive trial results

Jul 30, 2024, 8:00 AM EDT - 1 year ago

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

Jul 29, 2024, 4:05 PM EDT - 1 year ago

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Jun 24, 2024, 8:30 AM EDT - 1 year ago

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

jjegglie Sep. 16 at 8:40 PM

$IMNN I provide celsion life lessons at zero cost, yet so many choose to think they know more about this stock promotion scam corporation than me and learn their own lessons at great cost.

0 · Reply

Golferhack12 Sep. 16 at 7:36 PM

0 · Reply

3ARated Sep. 16 at 2:37 PM

$IMNN When do they turn out the lights?

1 · Reply

WavyTraders Sep. 12 at 8:45 PM

1 · Reply

HiPpYcHoP Sep. 11 at 9:51 PM

$IMNN WhaT’s GoiN oN? We MoViN AH!

0 · Reply

ddgcabd Sep. 11 at 1:26 PM

$IMNN $LLY $AZN $JNJ As soon as you come to grips with the fact that celsion doesn't give a single shit about cancer, everything they do starts to make perfect sense.

0 · Reply

ConcernedCitizen23 Sep. 11 at 11:46 AM

0 · Reply

I_AM_GROOT Sep. 11 at 12:26 AM

$IMNN doubt it was from her personal cash. Bonuses can come via stock .

1 · Reply

Charleygolden Sep. 10 at 6:59 PM

$IMNN AKA $.37.

0 · Reply

Phil212 Sep. 10 at 12:25 PM

2 · Reply

3ARated Sep. 9 at 3:03 PM

$IMNN He wrote almost the same thing about INAB

1 · Reply

NVDAMillionaire Sep. 9 at 1:04 PM

$IMNN Excellent article that nails exactly where IMNN stands right now. So if you want to update your IMNN knowledge or get acquainted with IMNN, this is a must read. https://beyondspx.com/quote/IMNN/analysis/imunon-ovation-2-s-unprecedented-survival-data-positions-dna-immunotherapy-for-pivotal-phase-3-nasdaq-imnn

3 · Reply

Groggok Sep. 8 at 9:33 PM

$IMNN https://www.linkedin.com/posts/imunon_aacrovca25-ovariancancer-activity-7370905039223136256-HfS-?utm_medium=ios_app&rcm=ACoAAACmFJwBPatFGkGz2_7iNc5YyQwovqc3gW8&utm_source=social_share_send&utm_campaign=copy_link

0 · Reply

jjegglie Sep. 8 at 9:06 PM

$IMNN Sleazy Statborg has already lied so consistently and audaciously that the market just yawns when she tries to manipulate the share price. Longs to get thoroughly rug-ed any day now. Company is within just a few weeks of running put of cash.

0 · Reply

ConcernedCitizen23 Sep. 8 at 1:09 PM

$IMNN everybody should watch the investor presentation on their website…she also said news coming next two months

2 · Reply

ConcernedCitizen23 Sep. 6 at 6:34 PM

$IMNN the ceo at about 15:00 said that there’s a 90% the phase 3 trial will be terminated early for success!

4 · Reply

Krigg Sep. 6 at 12:21 PM

$IMNN Here is a quote from the web cast yesterday: " So the hazard ratio in all patients was 0.69. It's an impressive hazard ratio. It dropped to 0.38. I can't give you the difference in median survival, because half of the women in the Imunon arm that were treated with PARP inhibitors are still alive. So the median hasn't been observed."

3 · Reply

Goldpay55 Sep. 4 at 5:33 PM

$IMNN Heading i to the $4's by next Friday at this pace.

0 · Reply

Charleygolden Sep. 3 at 9:05 PM

$IMNN AKA $.38.

0 · Reply

ConcernedCitizen23 Sep. 3 at 8:21 PM

$IMNN it’ll be very fun to watch the bears burn

2 · Reply

Goldpay55 Sep. 3 at 7:59 PM

$IMNN looks like 5.60 tomorrow. -0.10

0 · Reply

I_AM_GROOT Sep. 3 at 7:52 PM

$IMNN just wait until they drop that next offering.. Then again after the epic drop new bulls will appear after the carnage..

0 · Reply

Market Cap	14.03M
Revenue (ttm)	0.00
Net Income (ttm)	-18.62M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	61,600
Avg Vol	238,882
Day's Range	N/A - N/A
Shares Out	2.44M
Stochastic %K	15%
Beta	2.29
Analysts	Strong Sell
Price Target	$25.09